Doxorubicin (adriamycin) cardiomyopathy

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Doxorubicin hydrochloride (Adriamycin) is a vital chemotherapy agent.
• Its clinical use is restricted by dose-limiting cardiotoxicity, specifically cardiomyopathy.
• Understanding this toxicity is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To critically review the cardiotoxicity of doxorubicin hydrochloride.
• To examine the natural history, histopathology, risk factors, and monitoring of this adverse effect.
• To analyze proposed mechanisms and current prevention strategies.

Main Methods:

• Literature review of natural course, histopathology, and risk factors.
• Analysis of proposed mechanisms of doxorubicin-induced cardiomyopathy.
• Evaluation of preventive agents and administration methods.

Main Results:

• Doxorubicin-induced cardiomyopathy is a significant clinical concern.
• Mechanisms involve free radical damage, enzyme inhibition, and altered calcium levels.
• Various agents (e.g., antioxidants, nucleosides) and liposomal delivery show promise for prevention.

Conclusions:

• Doxorubicin cardiotoxicity necessitates careful monitoring and risk assessment.
• Further research into underlying mechanisms can guide the development of effective cardioprotective strategies.
• Novel delivery systems and pharmacological interventions may mitigate this severe side effect.